Maslowski John Michael 4
4 · Fibrocell Science, Inc. · Filed Dec 13, 2019
Insider Transaction Report
Form 4
Maslowski John Michael
VP, Scientific Affairs
Transactions
- Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−908→ 0 totalExercise: $232.50Exp: 2021-01-14→ Common Stock (908 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−1,334→ 0 totalExercise: $44.10Exp: 2024-05-13→ Common Stock (1,334 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−6,668→ 0 totalExercise: $52.95Exp: 2025-01-20→ Common Stock (6,668 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−6,667→ 0 totalExercise: $34.05Exp: 2026-03-01→ Common Stock (6,667 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−16,667→ 0 totalExercise: $9.94Exp: 2026-12-16→ Common Stock (16,667 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−20,000→ 0 totalExercise: $3.45Exp: 2028-01-25→ Common Stock (20,000 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−1,167→ 0 totalExercise: $82.35Exp: 2023-07-19→ Common Stock (1,167 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−1,334→ 0 totalExercise: $74.25Exp: 2024-01-17→ Common Stock (1,334 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−100,000→ 0 totalExercise: $1.78Exp: 2029-04-12→ Common Stock (100,000 underlying) - Disposition to Issuer
Common Stock
2019-12-13$3.00/sh−3,164$9,492→ 0 total
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00.
- [F2]Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price.